Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis

Acta Dermato-Venereologica

Volumn 94, Issue 3, 2014, Pages 363-364

  Kibsgaard, Line ^a   Skjold, Tina ^a   Deleuran, Mette ^a   Vestergaard, Christian ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOGLOBULIN E; INOTROPIC AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; TRYPTASE; ANTIALLERGIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADULT; ALLERGIC RHINITIS; ANAPHYLAXIS; BIRCH; BONE MARROW; BONE MARROW BIOPSY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DARIER DISEASE; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; EMERGENCY WARD; ENZYME BLOOD LEVEL; FLUSHING; GRASS; HEAT; HISTOPATHOLOGY; HUMAN; HYPOTENSION; INFLAMMATORY INFILTRATE; INGUINAL LYMPH NODE; INOTROPISM; INTENSIVE CARE UNIT; LIMB; LYMPHADENOPATHY; MALE; MAST CELL; NOTE; ONCOGENE C KIT; OUTPATIENT DEPARTMENT; POINT MUTATION; PRIORITY JOURNAL; RASH; REMISSION; SKIN EXAMINATION; SPLENOMEGALY; SYSTEMIC MASTOCYTOSIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT DURATION; TRUNK; ULTRASOUND; URTICARIA PIGMENTOSA; DRUG EFFECTS; IMMUNOLOGY; MASTOCYTOSIS, SYSTEMIC; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MALE; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84899945914     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1687     Document Type: Note

References (15)

1. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: Practical recommendations. Am J Clin Dermatol 2011; 12: 259-270
2. Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86: 362-371
3. Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: A study on history, clinical features and risk factors in 120 patients. Allergy: Eur J Allergy Clin Immun 2008; 63: 226-232
4. Akin C. Anaphylaxis and mast cell disease: What is the risk? Curr Allergy Asthm R 2010; 10: 34-38
5. González De Olano D, De La Hoz Caballer B, Núnez López R, Sánchez Munoz L, Cuevas Agustin M, Diéguez MC, et al. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: A study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy 2007; 37: 1547-1555
6. Wimazal F, Geissler P, Shnawa P, Sperr WR, Valent P. Severe life-threatening or disabling anaphylaxis in patients with systemic mastocytosis: A single-center experience. Int Arch Allergy Immunol 2012; 157: 399-405
7. Horan RF, Austen KF. Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991; 96: 5-14
8. Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine 1988; 67: 345-368
9. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112: 946-956
10. Beck LA, Marcotte GV, MacGlashan Jr D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immun 2004; 114: 527-530
11. MacGlashan Jr DW, Bochner BS, Adelman DC, Jardieu PM, Togias A, McKenzie-White J, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immun 1997; 158: 1438-1445
12. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/ GALEN/EDF/WAO guideline: Management of urticaria. Allergy: Eur J Allergy Clin Immun 2009; 64: 1427-1443
13. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immun 2007; 119: 1550-1551
14. Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012; 108: 383-384
15. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O'Hehir RE. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy: Eur J Allergy Clin Immun 2010; 65: 926-927.